Kronos Bio Inc., a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right (CVR), which represents the right to receive: 50% of the net proceeds in the case of a disposition of t...